Goldman Sachs’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-742,905
| Closed | -$20.8M | – | 6933 |
|
|
2022
Q1 | $20.8M | Buy |
742,905
+121,194
| +19% | +$3.32M | ﹤0.01% | 2016 |
|
|
2021
Q4 | $17M | Buy |
621,711
+184,087
| +42% | +$4.99M | ﹤0.01% | 2278 |
|
|
2021
Q3 | $11.9M | Buy |
437,624
+273,347
| +166% | +$6.76M | ﹤0.01% | 2553 |
|
|
2021
Q2 | $2.81M | Sell |
164,277
-48,620
| -23% | -$910K | ﹤0.01% | 3892 |
|
|
2021
Q1 | $4.45M | Buy |
212,897
+13,878
| +7% | +$320K | ﹤0.01% | 3234 |
|
|
2020
Q4 | $4.56M | Sell |
199,019
-10,670
| -5% | -$203K | ﹤0.01% | 3074 |
|
|
2020
Q3 | $3.42M | Sell |
209,689
-22,503
| -10% | -$408K | ﹤0.01% | 3188 |
|
|
2020
Q2 | $3.14M | Sell |
232,192
-167,582
| -42% | -$1.95M | ﹤0.01% | 3136 |
|
|
2020
Q1 | $4.74M | Sell |
399,774
-121,950
| -23% | -$2.7M | ﹤0.01% | 2692 |
|
|
2019
Q4 | $13M | Buy |
521,724
+135,718
| +35% | +$2.75M | ﹤0.01% | 2236 |
|
|
2019
Q3 | $6.57M | Sell |
386,006
-8,015
| -2% | -$146K | ﹤0.01% | 2659 |
|
|
2019
Q2 | $8.97M | Buy |
394,021
+264,608
| +204% | +$7.14M | ﹤0.01% | 2442 |
|
|
2019
Q1 | $4.16M | Sell |
129,413
-61,331
| -32% | -$1.9M | ﹤0.01% | 3124 |
|
|
2018
Q4 | $5.38M | Sell |
190,744
-46,997
| -20% | -$1.38M | ﹤0.01% | 2816 |
|
|
2018
Q3 | $6.83M | Buy |
237,741
+5,273
| +2% | +$158K | ﹤0.01% | 2751 |
|
|
2018
Q2 | $8.71M | Buy |
232,468
+153,799
| +196% | +$6.04M | ﹤0.01% | 2511 |
|
|
2018
Q1 | $3.09M | Buy |
78,669
+30,245
| +62% | +$1.1M | ﹤0.01% | 3271 |
|
|
2017
Q4 | $1.57M | Sell |
48,424
-41,812
| -46% | -$1.25M | ﹤0.01% | 3978 |
|
|
2017
Q3 | $2.81M | Sell |
90,236
-33,463
| -27% | -$990K | ﹤0.01% | 3677 |
|
|
2017
Q2 | $3.46M | Buy |
123,699
+20,816
| +20% | +$471K | ﹤0.01% | 3373 |
|
|
2017
Q1 | $1.76M | Sell |
102,883
-11,241
| -10% | -$157K | ﹤0.01% | 3872 |
|
|
2016
Q4 | $1.38M | Sell |
114,124
-44,832
| -28% | -$580K | ﹤0.01% | 4182 |
|
|
2016
Q3 | $2.52M | Buy |
158,956
+144,421
| +994% | +$2.18M | ﹤0.01% | 3630 |
|
|
2016
Q2 | $188K | Buy |
+14,535
| New | +$228K | ﹤0.01% | 5739 |
|
|
2016
Q1 | – | Sell |
-63,665
| Closed | -$1.43M | – | 7401 |
|
|
2015
Q4 | $1.43M | Buy |
+63,665
| New | +$1.26M | ﹤0.01% | 3947 |
|
|
2015
Q2 | – | Sell |
-17,123
| Closed | -$442K | – | 7509 |
|
|
2015
Q1 | $442K | Sell |
17,123
-24,577
| -59% | -$562K | ﹤0.01% | 5265 |
|
|
2014
Q4 | $774K | Sell |
41,700
-6,971
| -14% | -$125K | ﹤0.01% | 4854 |
|
|
2014
Q3 | $754K | Buy |
+48,671
| New | +$733K | ﹤0.01% | 4901 |
|
Goldman Sachs's XENT Position: Q2 2022 in Review
Goldman Sachs sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 742,905 shares — an estimated $20.8M sold.
Goldman Sachs first reported a position in XENT in Q3 2014 and held it in 28 quarters. The position peaked at $20.8M in Q1 2022. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- Goldman Sachs reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- Goldman Sachs sold 742,905 Intersect ENT, Inc shares in Q2 2022, an estimated $20.8M.
- Goldman Sachs first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 28 quarters.
- Goldman Sachs's Intersect ENT, Inc position peaked at $20.8M in Q1 2022.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.